COX-2 expression was common in DCIS and invasive breast cancer (pooled estimates in the studies of 53% and 42% respectively), and there was no significant difference in prevalence of COX-2 expression between these lesions. This evidence concerns the gene PTGS2 and ductal breast carcinoma in situ.